News
Biosimilar onslaught will slow Roche down in 2018
Roche has recorded a successful full year 2017, with sales driven by MS drug Ocrevus and cancer treatments Tecentriq, Perjeta and Alecensa, helping it to boost overall sales by 5% to C
